This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-2 summaryPALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled ARsPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresIBRANCE long-term safetyGI and liver toxicitiesEffect of IBRANCE on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyRW evidenceValue of RWEWhat is real-world evidence?What is the value of RWE?P-REALITY and P-REALITY XP-REALITY OverviewP-REALITY OS and rwPFSP-REALITY X OverviewP-REALITY X OS and rwPFSIRISIRIS OverviewIRIS PFS and OSPOLARIS POLARIS OverviewPOLARIS Patient-Reported OutcomesMADELINEMADELINE OverviewMADELINE Patient CharacteristicsMADELINE Patient-Reported OutcomesPalomAGEPalomAGE OverviewRWE in Older Patients with mBCPatient-reported outcomesPALOMA-2: FACT-B scoresPALOMA-3: EORTC QLQ-C30 scoresPALOMA-3: Time to deterioration in pain symptomsDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provision ResourcesMaterials
PALOMA-3 progression-free survival

In PALOMA-3, IBRANCE in combination with fulvestrant in 1st line or later doubled mPFS vs placebo + fulvestrant in patients with progression on/after ET*1,2​​​​​​​

PALOMA-3 PFS* Kaplan-Meier Curve1,2

In a 2:1 randomised, double-blind, Phase III trial of women with HR+/HER2- mBC whose disease progressed following ET (N=521)2

Adapted from Cristofanilli M, et al. 20162 and IBRANCE SmPC.1​​​​​​Evaluated according to RECIST Version1.1.2Data cut-off date: March 16, 2015.
Updated non-prespecified analysis.
Data cut-off date: October 23, 2015.lmprovement in PFS was seen across a broad range of patients

IBRANCE in combination with fulvestrant reduced the risk of disease progression vs placebo+fulvestrant in multiple pre-defined patient subpopulations2,3

Subpopulations included:
  •  
  • Pre-/peri-menopausal women
  • Elderly patients (≥65 years)
  • Patients with visceral metastases
  •  
PALOMA-3 PFS Subgroup Analyses2,3*Adapted from IBRANCE EPAR Public assessment report.3
Data cut-off: 23 October 2015.
*Visceral metastasis was defined as lung, liver, brain, pleural, or peritoneal involvement.2 Sensitivity to prior hormonal therapy is defined as either a) documented clinical benefit (i.e. complete response, partial response or stable disease ≥24 weeks) to at least 1 prior hormonal therapy in the metastatic setting or b) at least 24 months of adjuvant hormonal therapy prior to recurrence.3Disease-free interval is time from diagnosis of primary breast cancer to first relapse in patients who received adjuvant therapy.3 Aromatase inhibitor = anastrazole, letrozole or exemestane. Anti-estrogen = tamoxifen, tamoxifen citrate, toremifene, or toremifene citrate.Other = neither an aromatase inhibitor nor an anti-estrogen.*Evaluated according to RECIST Version 1.1.¹Explore More PALOMA-2

See PALOMA-2 progression-free survival data

 Learn more
Cl = confidence interval; ECOG = Eastern Oncology Cooperative Group; ET= endocrine therapy; FUL = fulvestrant; HR = hazard ratio; ITT = intention to treat; HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; mBC = metastatic breast cancer; mPFS = median progression-free survival; n = number of patients; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors; SmPC = Summary of Product Characteristics.References:IBRANCE Summary of Product Characteristics.
Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
IBRANCE EPAR Public assessment report. 25 Nov 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003853/WC500217198.pdf. Accessed January 2023.
PALOMA-3 IBRANCE in the real-world setting Discover how patients responded to IBRANCE combination therapy in the real-world setting
 Find out more
IBRANCE Summary of Product Characteristics Product Characteristics Loading

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0589. January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.